AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03751306 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial Photobiomodulation
Description: Photobiomodulation Rehabilitation:~Diode laser, λ infrared = 810 nm, 0.028 cm2 beam area, 100 mW power, 3.5 W / cm2 power density, 3 Joules / dot and Energy Density of 107.1 J / cm2). Each point will be radiated for 30 seconds. The regions of irradiation will be in the middle cerebral arteries (points F7 and F8 will be used as reference point according to the International System 10-20 of the electroencephalogram) and anterior cerebral artery (AFz point according to the International System 10-20 of the electroencephalogram) .
Study NCT03751306 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Photobiomodulation (Placebo)
Description: Photobiomodulation Placebo Therapy:~The same apparatus of the transcranial group photobiomodulation and the same irradiation points will be used. However, during the procedure, with the laser off.
Study NCT03751306 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiorespiratory Rehabilitation
Description: Cardiorespiratory Rehabilitation:~Aerobic training on the treadmill will be reliated for 30 minutes using the support of the Rehabilitation and Physical Activity Station BrainMov® (equipment with 4 pillars condition that favors the suspension and stabilization of people with neuromuscular dysfunctions of mild to severe impairment. For monitoring, the training heart rate equation - Karvonen equation, effort perception scale - BORG, systemic arterial pressure, peripheral oxygen saturation, and patient signs and symptoms will be used. Subsequently, respiratory exercises and muscle strengthening of lower limbs, final relaxation and general guidelines will be performed for research volunteer and his / her relatives.
Study NCT03751306 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory Rehabilitation
Description: Cardiorespiratory Rehabilitation:~Aerobic training on the treadmill will be reliated for 30 minutes using the support of the Rehabilitation and Physical Activity Station BrainMov® (equipment with 4 pillars condition that favors the suspension and stabilization of people with neuromuscular dysfunctions of mild to severe impairment. For monitoring, the training heart rate equation - Karvonen equation, effort perception scale - BORG, systemic arterial pressure, peripheral oxygen saturation, and patient signs and symptoms will be used. Subsequently, respiratory exercises and muscle strengthening of lower limbs, final relaxation and general guidelines will be performed for research volunteer and his / her relatives.
Study NCT03751306 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cardiorespiratory Rehabilitation
Description: Cardiorespiratory Rehabilitation:~Aerobic training on the treadmill will be reliated for 30 minutes using the support of the Rehabilitation and Physical Activity Station BrainMov® (equipment with 4 pillars condition that favors the suspension and stabilization of people with neuromuscular dysfunctions of mild to severe impairment. For monitoring, the training heart rate equation - Karvonen equation, effort perception scale - BORG, systemic arterial pressure, peripheral oxygen saturation, and patient signs and symptoms will be used. Subsequently, respiratory exercises and muscle strengthening of lower limbs, final relaxation and general guidelines will be performed for research volunteer and his / her relatives.
Study NCT04335201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defibrotide Injection
Description: Patients will be treated according to the standard institutional procedures and will receive the best available treatment as per institutional guidelines in association with the experimental drug: Defibrotide 25 mg/kg body weight total dose in 2 hours duration infusion each, every 6 hours (Defibrotide 6.25 mg/kg body weight each dose) Treatment duration = 7 days
Study NCT02661711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: 2mg of 40mg/ml of Eylea Solution administered via intravitreal injection every four weeks for three months (loading dose), followed by a treat and extend protocol up to 12 months. Extension from monthly to 6, 8, 10 and 12 week follow up will occur where there is no reduction in macula oedema compared with the previous visit.~Number of cycles; minimum of 5 injections and maximum of 13 injections per study eye.
Study NCT02677324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT199
Description: Oral BCL-2 antagonist
Study NCT01501643 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spirometry
Description: Every two hours during the day with 10 maximum inspirations and at night if the patient is awake
Study NCT01999738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC1456 and EC20
Description: EC1456 is small molecule drug conjugate of folic acid and tubulysin B hydrazide (TubBH) that specifically binds to the membrane-bound FR and gains entry into the cell via endocytosis.~EC20 is Etarfolatide, a conjugate of folic acid and a tripeptide moiety that can efficiently chelate the radioisotope 99mTechnetium (99mTc). When etarfolatide is labeled with 99mTc, the product (99mTc-etarfolatide) is able to quantify FR expressing tissues with SPECT imaging.
Study NCT01895361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SelG1
Study NCT01895361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01595945 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Gastric bypass
Description: Subjects with a planned gastric bypass surgery are followed-up for resting metabolic rate.
Study NCT01595945 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Caloric restriction
Description: Subjects receive caloric restriction as calculated by an online weight management program and are followed-up for resting metabolic rate.
Study NCT02447783 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Capsules
Description: Cocoa-based, flavanol-free, control-matched capsules consumed for 12 weeks (Week 1: 2 capsules/day; Week 2: 3 capsules/day; Week 3-12: 4 capsules/day; Week 12-14: no capsule intake).
Study NCT02447783 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mars Cocoa Extract Capsules
Description: Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process and containing 500 mg of cocoa flavanols per capsule consumed for 12 weeks (Week 1: 2 capsules/day; Week 2: 3 capsules/day; Week 3-12: 4 capsules/day; Week 12-14: no capsule intake).
Study NCT03343964 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Amplitude-integrated electroencephalography
Description: Amplitude-integrated EEG (aEEG) is a compressed form of real-time conventional EEG monitoring that will be added to cEEG monitoring.
Study NCT02530333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Prevention Program
Description: Participants in the intervention group will complete at 6 week ACL injury prevention program previously described in the literature as being effective at reducing ACL injury risk. The prevention program lasts 20-25 minutes in duration and will take place as a warm-up prior to any practice. The frequency will depend solely on the number of practices each team holds throughout the given 6-week time period.
Study NCT01254344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ertapenem sodium
Description: Ertapenem sodium 1 g administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
Study NCT01254344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone sodium
Description: Ceftriaxone sodium 2 g administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
Study NCT01254344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to metronidazole
Description: Placebo (0.9% sodium chloride) administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
Study NCT01254344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazole
Description: Metronidazole 500 mg administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
Study NCT04744558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low carb high fat ketogenic dieting
Description: Macronutrient ratios for low carb high fat ketogenic diet were 20 %, 5 %, 75 % of protein, carbohydrates and fat, respectively. Caloric intake for experimental phase was set to cover basal metabolism and sedentary activities (BMR times 1.2) for every participant using the Mifflin St Jeor equation.
Study NCT04744558 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low carb high fat non-ketogenic dieting
Description: Macronutrient ratios for low carb high fat non-ketogenic diet were 20 %, 15 %, 65 % of protein, carbohydrates and fat, respectively. Caloric intake for experimental phase was set to cover basal metabolism and sedentary activities (BMR times 1.2) for every participant using the Mifflin St Jeor equation.
Study NCT01851096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNX-5422
Description: Capsules dosed every other day in the morning starting at a dose of 50 mg/m2. Dose escalation based on safety. Subjects will also receive 150 mg erlotinib daily (in the afternoon).
Study NCT01677754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4602522
Description: Participants will receive RO4602522 orally once daily for 12 months.
Study NCT00467649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramlintide acetate (Symlin)
Description: subcutaneous injection (60 mcg or 120 mcg), immediately prior to major meals
Study NCT00467649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine])
Description: subcutaneous injection, dosing based on titration guidelines
Study NCT01677754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo for RO4602522 orally once daily for 12 months.
Study NCT01677754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil
Description: Stable dose as background medication
Study NCT00467649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])
Description: subcutaneous injection, dosing based on titration guidelines
Study NCT00467649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])
Description: subcutaneous injection, dosing based on titration guidelines
Study NCT00754390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moderate Calcium, Low phytate Diet
Description: Participants consumed diet containing 700 milligrams calcium and 440 milligrams of phytate for 4 weeks
Study NCT01677754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Stable dose as background medication
Study NCT00754390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moderate Calcium, High Phytate Diet
Description: Participants consumed diet containing 700 milligrams calcium and 1800 milligrams of phytate for 4 weeks
Study NCT03376555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flow Mediated Dilation with nitroglycerin
Description: BP cuff on a forearm, gel on the upper arm just above the elbow, and a Doppler ultrasound probe on the gel. The ultrasound measures vessel size and blood velocity. After a 3-minute resting measurement, the cuff inflates for 5 minutes to occlude forearm blood flow (BF). After the cuff deflates, we perform a second reading.~Sublingual nitroglycerin: The subject is supine. We measure blood pressure. Also, we perform ultrasonography at the brachial artery at the elbow during the procedure. Nurse places a 0.4 mg nitroglycerin tablet under the subject's tongue. The subject remains supine for 20 minutes following the nitroglycerin administration.
Study NCT00754390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Calcium, Low Phytate Diet
Description: Participants consumed diet containing 1900 milligrams calcium and 440 milligrams of phytate for 4 weeks
Study NCT00754390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Calcium, High Phytate Diet
Description: Participants consumed diet containing 1900 milligrams calcium and 1800 milligrams of phytate for 4 weeks
Study NCT03759275 — intervention group
Intervention type: OTHER
Intervention: pMDT(Baseline Investigation)
Description: The pMDT(Baseline Investigation) takes multi-model analgesia as the main technical means. Multimodal perioperative analgesia refers to the combination of analgesics, adjuvant drugs and analgesic techniques with different effects throughout the perioperative period to achieve the best curative effect of reducing postoperative acute and chronic pain.
Study NCT03376555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flow Mediated Dilation with nitroglycerin
Description: BP cuff on a forearm, gel on the upper arm just above the elbow, and a Doppler ultrasound probe on the gel. The ultrasound measures vessel size and blood velocity. After a 3-minute resting measurement, the cuff inflates for 5 minutes to occlude forearm blood flow (BF). After the cuff deflates, we perform a second reading.~Sublingual nitroglycerin: The subject is supine. We measure blood pressure. Also, we perform ultrasonography at the brachial artery at the elbow during the procedure. Nurse places a 0.4 mg nitroglycerin tablet under the subject's tongue. The subject remains supine for 20 minutes following the nitroglycerin administration.
Study NCT01677754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Memantine
Description: Stable dose as background medication in combination with AChEIs
Study NCT01677754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Stable dose as background medication in combination with AChEIs
Study NCT01677754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rivastigmine
Description: Stable dose as background medication
Study NCT01677754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Description: Stable dose as background medication
Study NCT01677754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Galantamine
Description: Stable dose as background medication
Study NCT01677754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Description: Stable dose as background medication
Study NCT02069158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212384
Description: iv administrartion
Study NCT03490981 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual (TAU)
Description: Participants assigned to TAU will receive standard medical care from their primary care provider including pain medications, brief advice (e.g., use of relative rest, application of heat or ice, other self-care strategies), or referral to pain-related adjunctive interventions (e.g., physical therapy), as indicated.
Study NCT03490981 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioral Therapy for Chronic Pain (Brief CBT-CP)
Description: Brief CBT-CP is a manualized protocol that includes six, 30-minute sessions over the course of 6 weeks. Brief CBT-CP session outlines and patient handouts are included in the appendix. Session one focuses on foundational pain education and the development of treatment goals. Session two emphasizes balanced engagement in physical activity and pleasurable events. Session three emphasizes skills training for easily implemented relaxation techniques. Sessions four and five focus on recognizing and modifying unhelpful thoughts that negatively impact pain. Session six focuses on relapse prevention and independent implementation of CBT-CP skills following treatment.
Study NCT02766842 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNB with ProCore needle
Description: The use of the standard ProCore needle to acquire diagnostic tissue
Study NCT02766842 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNB with SharkCore needle
Description: The use of new SharkCore needle to acquire diagnostic tissue
Study NCT02766842 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProCore needle
Description: This is the standard needle used currently to procure tissue from lesions under endoscopic ultrasound guidance
Study NCT02766842 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SharkCore needle
Description: This is the new FDA approved needle for tissue procurement under endoscopic ultrasound guidance.
Study NCT02726308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 5 mg I.V. Dexamethasone just before induction
Study NCT02726308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 ml/kg Ringer's lactate
Description: Intra-operative 10 ml/kg Ringer's lactate solution .
Study NCT02726308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30 ml/kg Ringer's lactate
Description: Intra-operative 30 ml/kg Ringer's lactate solution .
Study NCT05457894 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu-M, Inactivated split influenza vaccine
Description: solution for intramuscular injection, 0.5 ml
Study NCT05457894 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ultrix®, Inactivated Split Influenza Vaccine
Description: solution for intramuscular injection, 0.5 ml
Study NCT03500185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PFMT in group
Description: Participants randomized to this group will perform the PFMT protocol in a group, with physiotherapeutic supervision, lasting 1 hour, in the Outpatient Clinic of Gynecology of Hospital of Clinics of Porto Alegre (HCPA), for a period of 3 months. You will also be instructed to perform exercises at home. After this period, they will be reassessed and will follow the same protocol for another 3 months now at home. After this period, they will be evaluated again.
Study NCT03500185 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PFMT at home
Description: Randomized participants for this group will receive guidance on the home PFMT protocol on the day of the initial evaluation. They will be instructed to perform the exercises daily for a period of 3 months. After 3 months they will be re-evaluated and will follow the same protocol for another 3 months at home. After this period they will be evaluated again.
Study NCT00260442 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: 12 weeks, 3 times a week whole body resistance training
Study NCT00260442 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Resistance Training
Description: 12 weeks, 3 times a week whole body resistance training
Study NCT00260442 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary
Description: Absence of physical activity
Study NCT00260442 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sedentary
Description: Absence of physical activity
Study NCT01856764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% Roflumilast Cream
Description: Roflumilast 0.5% cream
Study NCT00444184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost/timolol fixed combination, travoprost
Study NCT02585427 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low glycemic index rice, high glycemic index rice, butter, olive oil and grapeseed oil
Study NCT01856764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Roflumilast formulation vehicle
Study NCT02724670 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: IGRT
Description: MR-based IGRT
Study NCT03516903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: ddMTX-LDE (Methotrexate carried by a lipid nanoemulsion)
Study NCT03516903 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-LDE (Lipid nanoemulsion)
Study NCT03516903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Folic acid pill
Study NCT03516903 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid
Description: Folic acid pill
Study NCT00466687 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 10mg/kg, slow IV infusion, Days 1 and 14
Study NCT00466687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: 150mg PO qd
Study NCT00466687 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: fluorescence in situ hybridization
Description: Targeting multiple genetic aberrations in isolated tumor cells.
Study NCT00466687 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: gene expression analysis
Study NCT00466687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique
Description: immunologic technique
Study NCT00466687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: laboratory biomarker analysis
Study NCT00474175 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: single dose (less than 1g) of a matching placebo gel
Study NCT00466687 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: biopsy
Study NCT04224545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine Pill
Description: Colchicine at a dose of 1 mg a day before surgery, 2, 3, 4, 5 days after surgery.